DMD # 74567

INTRODUCTION
Enzyme induction can lead to decreased systemic exposure of the inducing drug (auto-induction) or of a co-administered drug that is metabolized by the induced enzyme, and can result in increased formation of active or toxic metabolites that change the pharmacological and toxicological outcomes in the induced state compared to the non-induced state (Guengerich et al., 1990; Lin, 2006) . Since hepatocytes contain the full complement of transcription factors, metabolic enzymes and transporters as well as co-activators and co-repressors, isolated hepatocytes are now recognized as the most relevant and practical in vitro model for induction studies (Hewitt et al., 2007a; Hewitt et al., 2007c; Godoy et al., 2013) . Therefore, the use of plated human hepatocytes is considered to be the "gold standard" in vitro assay for induction-risk assessment.
Given the common goal of regulatory authorities and industry sponsors to be able to predict the occurrence and extent of induction in humans from preclinical studies, the Pharmaceutical Research and Manufacturers of America (PhRMA) published a white paper with the intent of suggesting best practices for in vitro and in vivo pharmacokinetic DDI studies (Bjornsson et al., 2003) . This was followed up with an additional white paper in which the Pharmaceutical Innovation Steering Committee, under the auspices of PhRMA, conducted a survey to understand the predictability of various in vitro experimental models for CYP induction that was used across the industry (Chu et al., 2009) . Since the publication of this white paper and survey, the FDA, EMA and the PMDA have issued updated guidances; DDI Draft Guidance for Industry (FDA, 2012) (EMA, 2012) . It is recognized that induction of CYP2C enzymes can be important. For example, rifampicin is known to increase the clearance of S-warfarin (CYP2C9 substrate), a narrow therapeutic index drug (Bidstrup et al., 2004) . However, challenges remain with generating reproducible in vitro CYP2C induction data, with a large enough induction signal across different lots of human donors, which can be used to assess the clinical risk of CYP2C-induction. Thus, could we consider alternative approaches to assess the CYP2C induction risk? Also, the EMA guideline on DDI (EMA, 2012) states that "strong inducers should be included as positive controls to verify functioning regulation pathways via PXR, Constitutive Androstane Receptor (CAR) and the Aryl hydrocarbon Receptor (AhR)". CITCO, at concentrations ≤100 nM, is the positive control recommended by the EMA for CAR induction in in vitro experiments. This is in contrast to the FDA guidance (FDA, 2012) which recommends DMD # 74567 phenobarbital (PB) at a concentration between 500 -1,000 µM as a positive control for induction of CYP2B6. Could either option be suitable to verify functioning CAR activity?
In order to address the aforementioned discussion points, the IWG approached IQ member companies as to which specific aspects of the recent DDI guidelines required further clarification and evaluation. The IWG then approached the EMA with questions developed from these responses requesting insights into the recommendations of the EMA and these questions were published online (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/ WC500002963.pdf). As a follow-up, the IWG conducted an anonymous survey within IQ to gather information about current practices for the conduct of human hepatocyte induction studies and how companies interpret the derived data. Responses to the survey were received from 19 companies, which included 17 large companies (>10,000 employees) and two medium-sized companies (1,000-10,000 employees). Information gathered from the survey is presented in this article together with data driven recommendations on suggested changes to current Regulatory Guidances. Given the complexity and detailed assessment necessary for the data interpretation and the timecourse objectives, we plan to publish this work in follow-up manuscripts.
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METHODS
The results presented in this article were obtained by conducting a survey of pharmaceutical companies that are members of the IQ Consortium. Survey questions were provided by members of the IWG (https://iqconsortium.org/initiatives/workinggroups/induction/). The questionnaires were formulated using Microsoft Excel (2010). compounds. In some instances, certain questions had a small degree of overlapping information but were collated in the area that provided the best context for the question.
Protocol questions focused on how studies were conducted at different organizations which provided information on data variability across companies. In addition, induction data were collected for individual batches of hepatocytes such that variability across batches could also be assessed and to assess CYP2B6 induction by CITCO and phenobarbital. In these cases, all data were generated using standard internal company methods. Data were also collected to ascertain the manner in which in vitro hepatocyte induction data were interpreted by different companies. Given that establishing an in vitro to in vivo extrapolation (IVIVE) was critical, in addition to collecting in vitro data, clinical data were also collected and collated. Finally, the team also sought to understand the types of questions that were received from regulators related to DMD # 74567 9 induction. This part of the survey was conducted using an online questionnaire and survey software (SurveyMonkey; www.surveymonkey.com).
The survey was conducted anonymously via the IQ Secretariat and sent to representatives of IQ Consortium member companies. Each representative was responsible for providing responses that were reflective of the company as a whole since only one response was collected from each company. The IWG received the blinded responses from the IQ Secretariat and could not identify specific responses from specific companies. Survey limitations include the following; a) the survey responses were blinded by the IQ Secretariat, which is a requirement for conducting surveys within the IQ consortium. Therefore it is not possible to follow-up with respondents to clarify information/data entries, etc.; b) the survey was sent to the Drug Metabolism Leadership Group representative of each member company with the request to have an internal expert complete the survey with appropriate input from others to represent the company's perspective and not that of the individual reporter. It was not possible to ensure that this was conducted as requested; c) IQ members may not have responded to all questions in the survey. As such, it is not possible to assess whether this introduced any bias in the survey responses; d) the IQ Induction Working Group tried to provide clear questions. As with all blinded surveys, it is not possible to assess whether the respondent interpreted the question differently; e) the survey was intended as a touch point to gain some insights into practices. The outcome of the survey is being used as one part of a strategy to develop a data based response to specific aspects of regulatory DDI guidances. The survey responses are not considered a definitive index of induction practices within the pharmaceutical industry. The DMD # 74567
RESULTS
Evaluation of Down-Regulation
Responses Observations of down regulation, (https://iqconsortium.org/initiatives/workinggroups/induction/)). Of the 17 respondents, 16 indicated that they have observed decreases in enzyme activity or mRNA levels during routine induction studies. In many cases companies use multiple formats, cytotoxicity methods and have observed decreases in multiple enzymes so the total is not always equal to the number of respondents (17). In nearly half of all companies, 10-20% of compounds screened for induction potential showed decreases in mRNA levels that were concentration dependent, unrelated to cytotoxicity and occurred across the enzymes evaluated (typically CYP1A2, CYP2B6 and CYP3A4), while a few companies also evaluated other enzymes and noted commensurate decreases (CYP2C8, CYP2C9 and UGT1A1) ( Figure 1B ). Thirteen companies observed decreases in mRNA <0.3-fold, of which 7 companies showed changes <0.1 ( Figure 1C ). In general, changes in mRNA levels appeared to be more sensitive than changes in enzyme activity. In most cases (7 of 11 responses) there was no clear correlation with structures, therapeutic area, or compound class when decreases in mRNA or activity were observed. Decreases in enzyme activity observed during routine in vitro induction studies can often be attributed DMD # 74567 to time-dependent inhibition (TDI) occurring over the incubation time-course (Fahmi et al., 2010) , as noted by 7 companies in the survey. In addition, when decreases in mRNA or enzyme activity are observed only at higher concentrations of an NCE, cytotoxicity is often a plausible mechanism which should be evaluated. Eight companies noted this as the mechanism. In cases where decreases in mRNA and/or enzyme activity are concentration dependent and not related to TDI or cytotoxicity, mechanistic studies could potentially aid in identifying the cause(s). Mechanisms which have been shown to mediate down-regulation of enzymes in vitro and/or in vivo could serve as a basis for designing follow-up studies (Dvorak et al., 2005; Lu et al., 2012; Lim et al., 2012; Healan-Greenberg et al., 2008) .
Of the 17 responding companies, 9 had no established cut-off criteria for downregulation, while the remaining companies used very similar cut-off criteria which included both >50% decrease and concentration dependence. Only 3 companies performed follow up mechanistic studies. Two of these studies involved a pre-clinical rat study where compound was administered and ex vivo mRNA levels and microsomal enzyme activity were measured. Due to variability in response, one study was deemed inconclusive. In the other study, down-regulation of drug metabolizing enzymes (DMEs) in rat hepatocytes had occurred at much higher concentrations of the NCE than was observed in human hepatocytes. In an ex vivo rat study, doses were selected which resulted in total systemic concentrations greater than the nominal in vitro incubation concentrations at which down-regulation was observed. In the prepared extracts, from treated rat livers, no changes in microsomal enzyme activity or mRNA levels were observed. Hence it was concluded that, in the rat, the in vitro down-regulation did not In addition to responding to the questionnaire, IQ member companies were asked to provide example questions received from regulators which were related to induction-based DDIs. Fourteen questions were submitted which were directly related to induction. Of these 14 questions, 4 were specifically targeted to gain a better understanding of NCE-mediated decreases in mRNA levels and enzyme activities observed during in vitro induction studies with human hepatocytes. Regulators' questions probed both for mechanistic insights and extrapolation to other enzymes that potentially could be down-regulated. Similar to TDI, down-regulation could result in exposure increases in patients. One regulatory question related to a small molecule which demonstrated decreases in mRNA levels and enzyme activity during the in vitro induction study and also showed in vitro TDI of some of the same enzymes. In that study, time-dependent decreases in activity for many of the enzymes evaluated were DMD # 74567 observed in a cocktail clinical DDI study and the applicant was asked to discuss whether down-regulation could be excluded as an additional mechanism; if it could not, which other enzymes might be affected.
In Vitro Assessment of CYP2C Induction
Ten companies responded to questions related to CYP2C induction. Similar to data in the literature (Yajima et al., 2014) , all companies reported variable CYP2C9 induction responses across different lots of hepatocytes, with induction values for CYP2C9 that were < 4-fold higher than vehicle control. Also, consistent with the literature, robust induction of CYP3A4 mRNA (12-to 47-fold) was observed in the same batches of hepatocytes ( Figure 2 ) (Yajima et al., 2014) . In order to negate the impact of protocol differences on the observed CYP2C mRNA inductive response between human hepatocyte donors, data were obtained from the same member company in 10 different batches of hepatocytes ( Figure 3 ). Again, while the CYP3A4 mRNA induction response to rifampicin was robust (8-to 80-fold), the extent of CYP2C8 and CYP2C9 mRNA induction ranged between 2-to 6-fold and 1.5-to 4-fold, respectively. While the CYP2C8 and CYP2C9 mRNA induction responses were low, there was a good correlation with the observed functional changes in enzyme activity. The survey results demonstrate a low magnitude of induction of CYP2C8 and CYP2C9 mRNA.
In contrast, data from the survey showed that increases in CYP2C19 activities were highly variable and were quite dramatic in some donors, up to 17-fold ( Figure 3 ).
In addition to data obtained with rifampicin, the IWG also compiled in vitro induction data for other compounds known to induce CYP2C isoforms (Supplementary Table 1 ).
This article has not been copyedited and formatted. The final version may differ from this version. Given that the pathways involved in the regulation of CYP2C and CYP3A4 are similar, it was not surprising to see positive correlations for induction between CYP3A4 and CYP2C mRNA, with r 2 values ranging from 0.6 to 0.99. Representative correlation plots for CYP2C and CYP3A4 enzymes, following induction by rifampicin, are shown in Figure 4 . This positive correlation can also be observed for bosentan, phenytoin and carbamazepine which cause varying extents of AUC decline of CYP2C9 probe substrates and CYP3A4 probe substrates in the clinic (Table 3) . Data in Table 3 summarize the percentage reduction of AUC of an in vivo CYP2C9 probe, S-warfarin, in response to various xenobiotics and the in vitro induction of CYP2C and CYP3A evoked by the same compounds. Rifampicin caused the greatest decrease in the AUC of Swarfarin and also induced CYP3A4 more than the other compounds. 
Positive Control for CYP2B6 Induction by CAR
DISCUSSION
Transcriptional down-regulation of CYPs by chemicals was identified as an area requiring further exploration over ten years ago (Riddick et al., 2004) . Despite this, published observations of drug-induced down-regulation by small molecules in vitro are scarce (Healan-Greenberg et al., 2008; Krausova et al., 2011; Yang et al., 2014; Zamek-Gliszczynski et al., 2014; Sager et al., 2017) . While potential mechanisms for down-regulation have been identified (as detailed below); none have established a clinical effect for the major inducible enzymes (CYP1A2, CYP2B6, CYP2C or CYP3A), from these in vitro observations. Indeed, when member companies were questioned as to whether the in vitro observations of down-regulation led to clinical changes in specific probe substrates, no examples were provided. The EMA indicated that they had one example from a sponsor where down regulation observed in human hepatocytes resulted in a clinical finding. Because of the confidentiality in submissions, additional details on this compound are not available at this time. A recent publication concluded that the IVIVE for bupropion mediated inhibition of CYP2D6 could be quantitatively predicted with the inclusion of down-regulation (Sager et al., 2017) , however the mechanisms behind the CYP2D6 down-regulation were not identified. There is also conflicting literature available with respect to the inducibility of CYP2D6. While CYP2D6
is generally thought to not be inducible (Ingelman-Sundberg, 2005; Teh and Bertilsson, 2012; Haertter, 2013 ), a recent publication shows that it can be induced in hepatocyte cultures in the absence of dexamethasone (Farooq et al., 2016) . More work is needed to confirm the in vitro observations from these two studies and to explore the cultures Lauschke et al., 2016) . Would long-term hepatocyte models offer advantages to evaluate down-regulation? Models have been developed which aim to improve the longevity and maintenance of activity of drug metabolizing enzymes and include co-culture models (Khetani and Bhatia, 2008; Krause et al., 2009 ), organotypic models (LeCluyse et al., 2012), 3D spheroid and flow systems (Soldatow et al., 2013) . However these models have not been as rigorously tested for induction as standard cultured hepatocyte models. Therefore, routine induction studies that satisfy current regulatory requirements are performed using sandwich cultured or monolayer hepatocytes. While reduced enzyme expression levels and activity offer a robust response window for induction, adequate basal levels are needed in order to characterize metabolism with and without down-regulation (Evers et al., 2013) .
Differences in culture conditions can also impact the basal levels of drug metabolizing enzymes and the ability of the culture to respond to cytotoxicity. An example was provided whereby the same unidentified company, using different culturing conditions at different sites, could not reproduce observed in vitro down-regulation. The exact reason for this difference was not determined. However, differences between sites in media formulations, plating format, donor used and culturing techniques may have contributed.
Additionally, the half-life of the end point being measured (mRNA or protein (enzyme activity) compared to the incubation time course need to be considered when interpreting in vitro data. While the half-life for mRNA of a given enzyme is shorter than the half-life for enzyme (Ramsden et al., 2015; Dixit et al., 2016) there can be differential turn-over observed between enzymes. As an example, differences in potency assessments for IL-6 mediated down-regulation of CYP3A4 mRNA have been observed between 48 and 72h incubation times (Evers et al., 2013) .
There is also a potential for cytotoxicity to occur, especially with the high in vitro concentrations used during an induction study. High compound test concentrations aim to cover potential gut concentrations and achieve levels sufficient enough to describe E max when induction is observed. While cytotoxicity is typically assessed during induction studies, most researchers use morphological assessment and end-point assays such as ATP, LDH, MTT, Presto Blue, WST-1 or monitoring of a house-keeping gene by TaqMan ( Figure 1B ). These assays are capable of detecting overt cytotoxicity.
In many cases more sensitive assays would be required to rule out a link between early This article has not been copyedited and formatted. The final version may differ from this version. cytotoxic events and down-regulation of enzymes. Setting stringent criteria for assessment of cytotoxicity (e.g. 20-25% cutoff compared with control) could help to avoid assigning significance to down-regulation which is the result of cytotoxicity.
Depending on the mode of hepatocyte toxicity, other assays may be more or less sensitive and this toxicity could also be compound dependent. There are potentially more sensitive approaches available to assess cytotoxicity such as high content imaging or systems such as xCelligence (Gerets et al., 2012; Grimm et al., 2015; Joshi and Lee, 2015; Li et al., 2015) . Overall, the potential for cytotoxicity to contribute to down-regulation should be considered as part of the complete picture toward developing an understanding of mechanisms behind these observations.
Alterations of the levels of CYP isoforms can occur through modulation of steroid receptors such as PXR, CAR, and AhR, with PXR and CAR partly regulated by the glucocorticoid receptor (GR) (Honkakoski and Negishi, 2000) . These signal transduction pathways can be affected at any step of the cascade, leading to CYP down-regulation, e.g. interference with binding of nuclear receptor retinoid-X receptor (RXR) with PXR, and disturbances with the cytoskeletal structure in the cell. A wellknown example of small molecule mediated down-regulation, in which these two mechanisms could be operative, is that of colchicine which has been shown to broadly reduce expression of CYPs, both in the basal state as well as in the induced state (Dvorak et al., 2003; Dvorak et al., 2005) . Colchicine is an anti-tubulin agent that inhibits the polymerization of microtubulin, and thus disrupts the dynamics of the microtubulin cellular skeletal structure, the structure that is considered necessary for the proper functioning of nuclear receptor signaling cascades (Lu et al., 2012) . A ). This could be relevant since TDI may be isoform specific whereas downregulation could potentially affect multiple co-regulated enzymes. In this case, when the mechanism of in vitro down-regulation occurs at the nuclear receptor, consideration of Examples of small molecules that disrupt interactions between nuclear receptors and co-activators involve sesamin in sesame oil (Lim et al., 2012) , camptothecin (Chen et al., 2010) , ketoconazole (Takeshita et al., 2002) and ET743 (Synold et al., 2001) . (Zhou et al., 2007; Zamek-Gliszczynski et al., 2014; Badolo et al., 2015; Shang et al., 2016) .
Metformin has been shown to specifically enhance the phosphorylation of CAR, thus blocking nuclear translocation and activation (Yang et al., 2014) . The challenges of describing down regulation in cultured hepatocytes are also reflected in the typically small signal for induction of CYP2C isoforms. A limited number of publications describe induction of human CYP2C8, CYP2C9, and CYP2C19 using either fresh or cryopreserved hepatocytes Raucy et al., 2002; Fahmi et al., 2010) . Moreover, the reports on induction of CYP2C isoforms are contradictory. For example, induction of CYP2C9 and CYP2C19 by rifampicin in human hepatocytes has been documented (Zilly et al., 1975; Gerbal-Chaloin et al., 2001 ) but others show no induction (Li et al., 1997; Runge et al., 2000; Dixit et al., 2015) .
Recently, Yajima et al. (Yajima et al., 2014) evaluated the induction of human CYP2C8, CYP2C9, and CYP2C19 mRNA using eight lots of cryopreserved human hepatocytes.
Following 72 hr incubation with rifampicin, induction of CYP2C8 and CYP2C9 mRNA was variable, while induction of CYP2C19 mRNA was not observed in any of the eight hepatocyte lots tested. Our results are consistent with the observation by Yajima et al. (Yajima et al., 2014) . Additionally, recent evidence also suggests that miRNA may impact the basal expression of CYP2C8 and CYP2C19 in human hepatocytes (Yu et al., This article has not been copyedited and formatted. The final version may differ from this version. 2015; Makia and Goldstein, 2016) . In vitro studies have also demonstrated that proteinprotein interactions occur between CYP2C9 and CYP3A4 which result in lower CYP2C9 activity with increasing levels of CYP3A4 (Subramanian et al., 2010; Ramsden et al., 2014) . In the human HepatoPac model, induction of CYP2C9 activity by rifampicin was greater when CYP3A4 levels were decreased by siRNA knockdown. Thus the apparent induction of CYP2C9 was dependent on the ratio of CYP2C9:CYP3A4 protein expression levels (Ramsden et al., 2014) . These factors may be responsible for the low magnitude and variable induction observed in our survey between the various CYP2C isoform mRNA induction responses. Additional mechanistic studies are needed to further understand the lack of robust induction and the variable response of CYP2C isoforms as determined by mRNA.
IVIVE approaches have been developed for induction of CYP3A to predict the potential of a compound to cause a clinically relevant DDI if co-administered with a compound that is primarily metabolized by CYP3A4 (Einolf et al., 2014) . Given that CYP3A4 shares transcriptional regulation factors with CYP2C, it may be possible to ascertain the risk of CYP2C induction based upon the risk assessment for CYP3A4 induction using static and dynamic models (Einolf et al., 2014) . genes by causing CAR to translocate from the cytoplasm to the nucleus where it binds to the phenobarbital-responsive enhancer module and increases transcription of downstream genes (Kawamoto et al., 1999) . Activation of CAR does not require direct binding of PB (Yang et al., 2014) . This is in contrast to CITCO which causes nuclear translocation by directly binding to the receptor (Xu et al., 2004) . These observations have led to two proposed mechanisms of CAR activation, "direct activation" which requires ligand binding and "indirect activation" which does not.
CYP2B6 induction can occur through activation of either CAR or PXR (Wang and Negishi, 2003) . The ligand binding profile of PXR is known to include a diverse array of drug-like molecules while the number of chemicals that activate CAR appears to be much less structurally diverse and shows considerable overlap with PXR activators (Mackowiak and Wang, 2016) . To date CITCO is the only chemical that has been shown to be highly selective for CAR over PXR. In transient transfection assays, CITCO displayed a >100-fold selectivity for CAR over PXR, with EC 50 values of 25 nM for CAR and ~3 μM for PXR (Maglich et al., 2003) . In contrast, PB has been shown to activate both CAR and PXR (Kawamoto et al., 1999; Sinz et al., 2006) although the degree of receptor selectivity has not been quantified.
In primary human hepatocytes it has been consistently shown that 100 nM CITCO induces CYP2B6, a concentration that is unlikely to activate PXR due to the selectivity described above. Increases in CYP2B6 mRNA, after treatment with 100 nM CITCO, were shown in 13 separate hepatocyte preparations (Maglich et al., 2003; DeKeyser et al., 2009; Sahi et al., 2009; Yang et al., 2010; Koh et al., 2012) . Eleven of the 13 donors showed a >2-fold increase in mRNA. Based on the data provided it could not be determined if the remaining 2 donors met this threshold. Additional data collected for this survey adds another 26 donors demonstrating a >2-fold increase in CYP2B6 mRNA by 100 nM CITCO. Thus, of the 39 total donors evaluated, 37 showed a response to 100 nM CITCO, defined as an increase in CYP2B6 mRNA >2-fold above This article has not been copyedited and formatted. The final version may differ from this version. and Fa2N4, lack CAR functionality (Kawamoto et al., 1999; Hariparsad et al., 2008) .
The data collected for this survey also demonstrated approximately equal or greater 
Summary and Recommendations:
-When a decrease in mRNA or activity is observed in vitro, there should be careful consideration of whether the decrease is concentration dependent and whether the compound is an inhibitor or an inactivator of the enzyme. Consideration should also be given to whether the decrease in mRNA or activity is linked to cytotoxicity or the mechanism of action.
-Correspondence with the EMA indicated that the Agency did have experience with down-regulation observed in human hepatocytes which was confirmed in vivo for one compound from a sponsor.
-Establishing an IVIVE in the absence of compounds which cause clinically relevant decreases in enzyme activity as a result of down regulation of enzymes, is currently not possible. As such, in vitro observations of down-regulation have to be considered with caution.
-Given the variable and low dynamic range of response in human hepatocytes, accurately predicting the potential for DDIs due to induction of CYP2C isoforms is challenging.
-Improved in vitro models with better dynamic range and less variability for the assessment of CYP2C induction are needed. Based upon co-regulatory pathways and positive correlation analyses, induction of CYP3A4 can be used as a sensitive marker of the potential for induction of CYP2C isoforms. Thus, a compound determined to have low risk to cause a CYP3A4-induction based DDI will have a very low risk to cause a CYP2C induction-based DDI.
This article has not been copyedited and formatted. The final version may differ from this version. 
CONCLUDING REMARKS
CYP induction has gained wide acceptance as an important factor for consideration in drug development, particularly as it relates to DDI (Hewitt et al., 2007a; Chu et al., 2009) . A number of factors have facilitated the emergence of human hepatocytes as the gold standard for the evaluation of CYP induction (Chu et al., 2009) , including improvements in the cryopreservation of hepatocytes (Saliem et al., 2012) and the consequent availability of large batches of human hepatocytes which can be characterized prior to routine use. The availability of cryopreserved human hepatocytes, from the same donor, in sufficient abundance, has also enabled the development of calibration models (Fahmi et al., 2008) which provides greater confidence to regulators for risk-based decision making. The continued progress in the understanding of induction requires collaboration between regulatory agencies and pharmaceutical companies with the overall goal of designing and conducting the most appropriate, necessary, and insightful clinical induction studies. It needs to be ensured that the design of preclinical studies is optimal. This survey of IQ member companies on current practices is intended as a step towards this goal, which, together with recommendations, specifically as they relate to key questions such as down-regulation, the in vitro assessment of CYP2C induction, as well as the use of CITCO as the in vitro CYP2B6 positive control will hopefully lead to optimized studies.
The IWG intends to publish our survey results and recommendations related to the data interpretation and the time-course objectives in follow-up manuscripts. Our (Gibbons et al., 2015) OmeprazoleCYP2C 19 in vivo Probe rifampicin -93 10 mg 600 mg (7 days) (Derungs et al., 2016) This article has not been copyedited and formatted. The final version may differ from this version. 
